CompletedPhase 2

Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)

South Korea27 participantsStarted 2015-05

Plain-language summary

This study will be conducted to evaluate the efficacy of Bendamustine Plus Rituximab (BR) in patients with relapsed or progressive Marginal Zone B-cell Lymphoma (MZBCL).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Histologically confirmed CD20-positive nodal or extranodal MZBCL
✓. MZBCL patients who relapsed or progressed:
✓. Patients age ≥ 18 years
✓. ECOG PS 0-2
✓. At least one bidimensionally measurable disease
✓. Adequate hematologic, renal, and hepatic functions
✓. Women of child-bearing potential should use two appropriate methods of contraception during the study
✓. Written informed consent

Exclusion criteria

✕. Not all of the above inclusion criteria are met.
✕. Prior chemotherapy within 4 weeks or radiotherapy within 6 weeks
✕. Corticosteroids during last 28 days except chronic administration of prednisolone at a dose of \< 20mg/day for indications other than lymphomas
✕. Evidence of CNS involvement by lymphomas
✕. Active HBV/HCV infections, known HIV infection
✕. Prior diagnosis of cancers within 5 years, except cervical intraepithelial neoplasia type 1, localized non-melanoma skin cancer, or small differentiated thyroid cancer
✕. Serious concurrent disease:
✕. Patients who are pregnant or lactating

What they're measuring

Overall Response Rate

Timeframe: Up to disease progression, more than 30.12 months

Trial details

NCT IDNCT02433795

SponsorSeoul National University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-10

Results submitted2025-12-29

View on ClinicalTrials.gov More Marginal Zone B-cell Lymphoma trials